- Study: Higher levels of sleep aid melatonin may reduce prostate cancer risk
- Real Health Labs launches Prostate Complete Once Per Day
- Study: Cough-cold manufacturers' voluntary label change on pediatric products reduced ER admissions
- Study: 2,000 IUs of vitamin E daily effective in slowing functional decline in AD patients
- Appropriations bill to boost funding for Lupus Research Institute's education program
INDIANAPOLIS — A drug made by Eli Lilly & Co. produced "significant" improvements in patients with erectile dysfunction who also had benign prostatic hyperplasia, according to results of a new study.
The phase-3 study, published in the Journal of Sexual Medicine, found that Cialis (tadalafil) improved erectile dysfunction and benign prostatic hyperplasia in men with both conditions. BPH is a condition in which the prostate enlarges, causing urinary symptoms.
The Food and Drug Administration approved Cialis to treat both conditions on Thursday.